{"url_path":"/sec/cadl/8-k/2026-05-15/item-7-01","section_key":"item-7-01","section_title":"Item 7.01 Regulation FD Disclosure.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1841387/0001193125-26-226751-index.html","accession_number":"0001193125-26-226751","cik":"0001841387","ticker":"CADL","issuer_name":"Candel Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1841387/0001193125-26-226751-index.html","primary_entity_key":"0001841387","primary_entity_name":"Candel Therapeutics, Inc."},"word_count":306,"has_tables":true,"body_markdown":"Item 7.01\n\nRegulation FD Disclosure.\n\nOn May 15, 2026, Candel Therapeutics, Inc. (the “Company”) held an investor presentation via live webcast to review extended follow-up data from the phase 3 clinical trial of aglatimagene besadenovec in localized prostate cancer, which was also presented by the Company during the American Urological Association 2026 Annual Meeting on May 15, 2026.\n\nA copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The presentation will also be available on the investor relations section of the Company’s website at https://ir.candeltx.com/. Information contained on the Company’s website is not incorporated by reference into this Current Report on Form 8-K, and you should not consider any information on, or that can be accessed from, the Company’s website as part of this Current Report on Form 8-K.\n\nAlso, on May 15, 2026, the Company issued a press release announcing the presentation at the American Urological Association 2026 Annual Meeting. A copy of the full press release is furnished as Exhibit 99.2 to this Current Report on Form 8-K and incorporated by reference herein.\n\nThe information in this Item 7.01 and Exhibits 99.1 and 99.2 of this Current Report on Form 8-K are furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibits 99.1 and 99.2 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing."}